Communicating drug benefits and risks effectively: There must be a better way

Annals of Internal Medicine

Volumn 150, Issue 8, 2009, Pages 563-564

  Avorn, Jerry ^a,b   Shrank, William H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG INFORMATION; EDITORIAL; GASTROESOPHAGEAL REFLUX; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; ADVERTIZING; CONSUMER HEALTH INFORMATION; HUMAN; METHODOLOGY; NOTE;

PRESCRIPTION DRUG;

ADVERTISING AS TOPIC; CONSUMER HEALTH INFORMATION; HUMANS; PRESCRIPTION DRUGS; RISK ASSESSMENT;

EID: 65349111822     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-8-200904210-00012     Document Type: Editorial

References (14)

1. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf; 2004.
2. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms. Two randomized trials. Ann Intern Med. 2009; 150:516-27.
3. Shrank WH, Agnew-Blais J, Choudhry NK, Wolf MS, Kesselheim AS, Avorn J, et al. The variability and quality of medication container labels. Arch Intern Med. 2007;167:1760-5. [PMID: 17846395]
4. Wolf MS, Shekelle P, Choudhry NK, Agnew-Blais J, Parker RM, Shrank WH. Variability in pharmacy interpretations of physician prescriptions. Med Care. 2009. [PMID: 19194338]
5. Shrank WH, Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health AfT (Millwood). 2007; 26:731-40. [PMID: 17485751]
6. Steering Committee for the Collaborative Development of a Long-Range Action plan for the provision of useful prescription medicine information. Action plan for the provision of useful prescription medicine information. Report submitted to The Honorable Donna E. Shalala, Secretary of the U.S. Department of Health and Human Services, December 1996. Accessed at www.fda.gov /cder/offices/ods/keystone.pdf on 19 February 2009.
7. Svarstad BL, Bultman DC, Mount JK. Patient counseling provided in community pharmacies: effects of state regulation, pharmacist age, and busyness. J Am Pharm Assoc (2003). 2004;44:22-9. [PMID: 14965149]
8. Kimberlin CL, Winterstein AG. Expert and consumer evaluation of consumer medication information. Accessed at www.fda.gov/cder/news/CMI/final- report .pdf on 16 February 2009.
9. Public Law 104-180. Title VI, Sec 601. Effective Medication Guides, 110 Stat 1593. 1996.
10. Wolf MS, Davis TC, Shrank WH, Neuberger M, Parker RM. A critical review of FDA-approved Medication Guides. Patient Educ Couns. 2006;62:316-22. [PMID: 16884888]
11. Kesselheim AS, Avorn J. Pharmaceutical promotion to physicians and First Amendment rights. N Engl J Med. 2008;358:1727-32. [PMID: 18420505]
12. www.RxFacts.org. Accessed 18 February 2009.
13. Hensley S. As drug bill soars, some doctors get an "unsales" pitch. Wall Street Journal. 2006; 13 March: 1.
14. Editorial: countering the drug salesmen. New York Times. 2008;20 March. Accessed at www.nytimes.com on 22 February 2009.